The effects of apheresis, storage time, and leukofiltration on microparticle formation in apheresis platelet products

Gao, Ming; Zhang, Bin; Zhang, Yue; Chen, Yuting; Xiong, Jian; Wang, Juan; Chen, Hanwei; Chen, Guoan; Qing, Wei

doi:10.1111/trf.14890

Cited by 8 publications

(11 citation statements)

References 25 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…72,73 Unlike cytokines, the PMP concentrations have no significant changes after LR. 72,76 PS externalization on PMPs surface staining with annexin-V is associated with desialylation, which promotes phagocytosis by HepG2 cells. 77 Some evidence has also suggested that PMPs from PC have potential for immune function due to proteins.…”

Section: Major Bmrs Released By Plateletsmentioning

confidence: 99%

“…Although different types of MPs can be detected in PCs, 72,73 we primarily focus on PMPs because the concentration of other cells in PCs is minimal. PMPs, small vesicles with a diameter of 0.1-1 microns, are primarily thought to be a way for platelets to exert coagulation function through membrane or intrinsic mediators because PMPs can trigger monocytic cell aggregation and release of procoagulant tissue factor-expressing MPs.…”

Section: Major Bmrs Released By Plateletsmentioning

confidence: 99%

“…In parallel, α‐granules release CD62P 30 to the membrane and soluble CD40 ligand (sCD40L) 66 and regulated on normal activation T cells expressed and secreted (RANTES) 67 to the extracellular space. Platelet microparticles (PMPs) 72 are also produced by platelets. (3) These BMRs including GPI bα, GPVI, PS and PMPs may be associated with reactive oxygen species (ROS) as demonstrated by elevated O 2 ‐ level 34 .…”

Section: Psls At 20–24°c Under Constant Horizontal Agitationmentioning

confidence: 99%

“…Microparticles (MPs) in circulating blood are platelet‐derived MPs (PMPs, Annexin‐V + /CD41a + ), red blood cell‐derived MPs (RMPs, CD235 + ), leukocyte‐derived MPs (LMPs, CD45 + ), monocyte‐derived MPs (MMPs, CD14 + ) and endothelial cell‐derived MPs (EMPs, CD144 + ). Although different types of MPs can be detected in PCs, 72,73 we primarily focus on PMPs because the concentration of other cells in PCs is minimal. PMPs, small vesicles with a diameter of 0.1–1 microns, are primarily thought to be a way for platelets to exert coagulation function through membrane or intrinsic mediators because PMPs can trigger monocytic cell aggregation and release of procoagulant tissue factor‐expressing MPs 74 .…”

Section: Psls At 20–24°c Under Constant Horizontal Agitationmentioning

confidence: 99%

See 3 more Smart Citations

The platelet storage lesion, what are we working for?

Liu,

Su,

Guo

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundPlatelet concentrate (PC) transfusions are crucial in prevention and treatment of bleeding in infection, surgery, leukemia, and thrombocytopenia patients. Although the technology for platelet preparation and storage has evolved over the decades, there are still challenges in the demand for platelets in blood banks because the platelet shelf life is limited to 5 days due to bacterial contamination and platelet storage lesions (PSLs) at 20–24°C under constant horizontal agitation. In addition, the relations between some adverse effects of platelet transfusions and PSLs have also been considered. Therefore, understanding the mechanisms of PSLs is conducive to obtaining high quality platelets and facilitating safe and effective platelet transfusions.ObjectiveThis review summarizes developments in mechanistic research of PSLs and their relationship with clinical practice, providing insights for future research.MethodsAuthors conducted a search on PubMed and Web of Science using the professional terms “PSL” and “platelet transfusion.” The obtained literature was then roughly categorized based on their research content. Similar studies were grouped into the same sections, and further searches were conducted based on the keywords of each section.ResultsDifferent studies have explored PSLs from various perspectives, including changes in platelet morphology, surface molecules, biological response modifiers (BMRs), metabolism, and proteins and RNA, in an attempt to monitor PSLs and identify intervention targets that could alleviate PSLs. Moreover, novel platelet storage conditions, including platelet additive solutions (PAS) and reconsidered cold storage methods, are explored. There are two approaches to obtaining high‐quality platelets. One approach simulates the in vivo environment to maintain platelet activity, while the other keeps platelets at a low activity level in vitro under low temperatures.ConclusionUnderstanding PSLs helps us identify good intervention targets and assess the therapeutic effects of different PSLs stages for different patients.

show abstract

Section: Major Bmrs Released By Plateletsmentioning

confidence: 99%

Section: Major Bmrs Released By Plateletsmentioning

confidence: 99%

Section: Psls At 20–24°c Under Constant Horizontal Agitationmentioning

confidence: 99%

Section: Psls At 20–24°c Under Constant Horizontal Agitationmentioning

confidence: 99%

See 2 more Smart Citations

The platelet storage lesion, what are we working for?

Liu,

Su,

Guo

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…These reactions may be due to the techniques used for processing, storage, and collection. 8 To improve PLT collection apheresis efficiency and quality, new instruments and improvements in cell collection technology are in constant development, aimed at reducing the duration of the procedure and its adverse effects. 9 Improvement of current plateletpheresis collection yields is a priority due to increased PLT demand, principally from hematooncology patients receiving myeloablative chemotherapy and hematology patients who require support after receiving a hematopoietic stem cell transplant.…”

Section: Introductionmentioning

confidence: 99%

Assessing the performance of a plateletpheresis unit at a tertiary‐care academic medical center in Mexico: A 6‐year experience

Jaime‐Pérez

Beltrán-López

Alvarado-Navarro

et al. 2021

J of Clinical Apheresis

View full text Add to dashboard Cite

BackgroundOptimization of platelet (PLT) apheresis collection is a priority to satisfy the increasing demand of hemato‐oncology patients. We assessed the performance of a plateletpheresis unit supporting hematology patients.Study design and methodsThis descriptive retrospective study included 561 plateletpheresis collections from 2013 to 2018. For data analysis, descriptive statistics and receiver operating characteristic (ROC) curve were used. A 5‐item satisfaction questionnaire was analyzed.ResultsNinety percent of the donors were males. The median plateletpheresis time was 89 minutes; its success rate was 92.5%; median donor PLT count was 232 × 109/L, women median PLT count was 247 × 109/L vs 231x109/L in men (P = .017). Seventy‐seven percent donors were candidates for a double product and 24.5% were processed; 20.8% of these donors had a weight ≤75 and 79.2% >75 kg, P = .003, and 6.6% were women and 93.4% men, P = .161. Thirty‐six of donors had ≥250 × 109/L and 16.8% was processed as a triple product. ROC analysis showed that with donor PLT counts ≥200 × 109/L the sensitivity for obtaining double products was 0.981 and specificity 0.714, with an area under the curve (AUC) = 0.877. The adverse effect rate was 4.3%. Of the potential donors, 6.3% were rejected. The cost of processing single or double products was 430 USD. Comfort and time spent during plateletpheresis were areas for improvement.ConclusionPlatelet count and donor weight predicted PLT yield and obtaining double products. Women had higher PLT counts, but no significant difference was found between donor gender and processed products. Assessment of the apheresis unit can help to improve its performance.

show abstract

Extracellular vesicles in the transfusion medicine field: The potential of proteomics

Hermida-Nogueira

García

2021

Proteomics

View full text Add to dashboard Cite

In transfusion centres, blood components are divided and stored following specific guidelines. The storage temperature and time vary among the blood cells but all of them release extracellular vesicles (EVs) under blood bank conditions. The clinical impact of such vesicles in blood components for transfusion is an object of debate, but should be considered and is being investigated. In this context, proteomics is an excellent tool to study the cargo and composition of EVs derived from red blood cells and platelets, since such vesicles are enriched in lipids and proteins. The development of quantitative mass spectrometry techniques and the evolution of bioinformatics have allowed the identification of novel EVs biomarkers for different diseases. In this context, the application of high coverage proteomic tools to the analysis of EVs in the transfusion medicine field would provide information about storage lesions and possible transfusion adverse reactions. This viewpoint article approaches the potential of proteomics to investigate the impact of EVs in blood bank transfusion components, especially red blood cells and platelets. K E Y W O R D S extracellular vesicles, proteomics, transfusion medicine EXTRACELLULAR VESICLES IN THE TRANSFUSION MEDICINE FIELDExtracellular vesicles (EVs) were depicted for the first time in 1967 when Peter Wolf described them as "platelet dust" [1]. Over the years, different studies confirmed that these small lipid particles come from different cellular types and reflect the processes that are taking part inside the cells. EVs are more complex than seemed at the beginning and have been classified according to their size, biochemical composition, and cell origin [2]. The traditional nomenclature divided EVs in three groups: exosomes, microvesicles (MV) or microparticles (MP), and apoptotic bodies. Since consensus has not yet emerged on specific markers of EV subtypes, currently The International Society of Extracellular Vesicles (ISEV) supports the use of the terms "small EVs"This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

The effects of apheresis, storage time, and leukofiltration on microparticle formation in apheresis platelet products

Abstract: MP formation was affected by the apheresis procedure. RMPs, LMPs and MMPs were lower after PLT apheresis. During storage, TMPs, PMPs, RMPs, LMPs, and MMPs were found to be higher in PLT supernatants. Leukofiltration exerted no significant effect on all MPs in PLT products.

Cited by 8 publications

References 25 publications

The platelet storage lesion, what are we working for?

The platelet storage lesion, what are we working for?

Assessing the performance of a plateletpheresis unit at a tertiary‐care academic medical center in Mexico: A 6‐year experience

Extracellular vesicles in the transfusion medicine field: The potential of proteomics

Contact Info

Product

Resources

About